看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。. E0 i- Y. ] b/ ?2 N
4 y/ x; O% T3 j, d1 N( ^ d! U5 G, v+ H
Currently available feasibility data for possible combination strategies. 5 W* O; P( y( j9 [3 X
————————————————————————————————
2 w- i0 R/ W$ ]/ `9 I, QCombination Feasibility according to preliminary data
2 s! w# b3 M' U4 _) s——————————————————————————————————
5 V! u/ T: h, hBevacizumab + sorafenib Yes, reduced dose
' @- ~5 l' G; M$ G" y4 w% }, HBevacizumab + sunitinib† No " }4 t4 \4 R. M9 [% h; L: C2 P
Bevacizumab + temsirolimus Yes 2 ` @% D4 _0 j, E
Bevacizumab + everolimus Yes ' @( z3 J) |- L" P5 h
Sorafenib + sunitinib ? & y; t% B8 ?1 B* m" P) `' N; C* S6 `
Sorafenib + temsirolimus Yes, reduced dose * s% a: g4 s# a2 }4 N6 r
Sorafenib + everolimus Yes, reduced dose * @/ v" N, j0 Q7 w7 a W
Sunitinib + temsirolimus† No 8 ^, k! r8 j/ h, V$ R4 @
Sunitinib + everolimus ?
2 ]) b; y: T/ vTemsirolimus + everolimus ? 7 E# H& ]6 N: T9 D( M) b
————————————————————
" J9 E4 z- r! _" h) O. x$ F7 z†Led to US FDA warning.2 D; D" N# P6 g, U( r: C1 Q2 B% S
?: As yet unattempted combination.- j% m5 r# d3 H/ j) o6 q4 d% ~
|